There are currently 2876 clinical trials in Houston, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including M D Anderson Cancer Center, University of Texas MD Anderson Cancer Center, Baylor College of Medicine and The University of Texas - MD Anderson Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Heart Coherence Training on Vascular Ehlers-Danlos Syndrome Patients
NCT05994664
Recruiting
Vascular Ehlers-Danlos Syndrome (VEDS) is caused by pathogenic variants of the COL3A1 gene, resulting abnormal Type III collagen protein. This impacts the body's connective tissue and makes people with VEDS at high risk of spontaneous aortic and arterial rupture, pneumothorax, and hollow organ perforation across the age spectrum. Given this risk and high potential for lethality, VEDS is considered the most severe type of Ehlers-Danlos Syndrome. In addition, many patients experience chronic pain... Read More
Gender:
ALL
Ages:
Between 12 years and 45 years
Trial Updated:
06/27/2024
Locations: Texas Children's Hospital, Houston, Texas
Conditions: Vascular Ehlers-Danlos Syndrome
Register for Updates
LSTR in Chevron Osteotomy
NCT06486753
Recruiting
The goal of this clinical trial is to determine if performing a lateral soft tissue release during a Chevron osteotomy (or Akin osteotomy when appropriate) for bunions leads to better correction without added complications in 200 patients over the age of 18 years old with the capacity to consent and mild to moderate bunions that are determined to benefit from Chevron osteotomies by one of the IRB approved study physicians. The main questions it aims to answer are: How does the addition of a lat... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2024
Locations: Houston Methodist Research Institute, Houston, Texas
Conditions: Bunion
Register for Updates
Post Approval Study2: Hintermann Series H3 Total Ankle Replacement System
NCT04770870
Recruiting
The H3 TAR Prosthesis was approved by FDA (P160036) on June 4, 2019. Continued approval of the premarket approval application (PMA) is contingent upon the submission of periodic reports (Annual Report), required under 21 CFR 814.84. In order to provide continued reasonable assurance of the safety and effectiveness of the PMA device, data from this post-approval study must be submitted to FDA in a PMA Post-Approval Study Report per the requirements set forth in the approval.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
06/24/2024
Locations: Spring Branch Podiatry, PLLC, Houston, Texas
Conditions: Osteoarthritis Ankle, Post-Traumatic Osteoarthritis of Ankle, Osteoarthritis of Ankle Secondary to Inflammatory Arthritis (Disorder)
Register for Updates
Reducing Alcohol Exposed Pregnancies
NCT05766761
Recruiting
The goal of this clinical trial is to compare an active intervention versus a standard of care control in reducing alcohol use among pregnant women. The main questions it aims to answer are whether a motivational intervention can: 1. increase the proportion of women detected with a laboratory-confirmed negative phosphatidylethanol (PEth) test during pregnancy, and 2. reduce the proportion of adverse birth outcomes among infants. Participants will be offered (1) a self-paced computer-delivered a... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/24/2024
Locations: The University of Texas Health Science Center, Houston, Houston, Texas
Conditions: Alcohol Drinking
Register for Updates
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
NCT05795595
Recruiting
This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX131™ in subjects with relapsed or refractory solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2024
Locations: Research Site 5, Houston, Texas
Conditions: Clear Cell Renal Cell Carcinoma, Cervical Carcinoma, Esophageal Carcinoma, Pancreatic Adenocarcinoma, Malignant Pleural Mesothelioma
Register for Updates
Care Coordination System for People With Dementia
NCT04308512
Recruiting
Dementia, a chronic disease of aging, is characterized by progressive cognitive decline that interferes with independent functioning. The medical, psychological, social and functional sequelae of dementia cause great stress to patients, their caregivers, and their family. The investigator proposes to examine effectivness of a home-based care coordination and management device, called Care4AD to help caregivers effectively coordinate, manage, and improve dementia care.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
06/21/2024
Locations: Baylor College of Medicine, Houston, Texas +1 locations
Conditions: Alzheimer Disease, Dementia, Dementia Alzheimers
Register for Updates
Oxytocin for Hypermobile Ehlers-Danlos Syndrome
NCT05405257
Recruiting
The purpose of this pilot study is to evaluate effect of IV oxytocin on chronic pain in patients with Hypermobile Ehlers Danlos syndrome.
Gender:
FEMALE
Ages:
Between 18 years and 64 years
Trial Updated:
06/21/2024
Locations: Baylor College of Medicine, Houston, Texas
Conditions: Hypermobile Ehlers-Danlos Syndrome, Pain Assessment
Register for Updates
Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma
NCT05948475
Recruiting
This study is a Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered, Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: The University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Cholangiocarcinoma
Register for Updates
A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection
NCT04706923
Recruiting
The purpose of this study is to determine the safety and tolerability of intravenous (IV) brincidofovir (BCV; SyB V-1901) 0.2 mg/kg, 0.3 mg/kg or 0.4 mg/kg dosed twice weekly (BIW) or 0.4 mg/kg dosed once weekly (QW) for 4 weeks in subjects with AdV, and IV BCV in subjects with CMV
Gender:
ALL
Ages:
2 months and above
Trial Updated:
06/20/2024
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Adenovirus Infections, Cytomegalovirus Infection
Register for Updates
Natural History Study and Establishment of a Biorepository-TANGO2-related Disorder
NCT05374616
Recruiting
The study aims to establish a biorepository of individuals with TANGO2 deficiency to support scientific research and establish a comprehensive clinical database of affected individuals to understand the disease course.
Gender:
ALL
Ages:
0 days and above
Trial Updated:
06/20/2024
Locations: Baylor College of Medicine, Houston, Texas
Conditions: TANGO2-related Disorder
Register for Updates
Metformin and Nightly Fasting in Women With Early Breast Cancer
NCT05023967
Recruiting
This phase IIb trial studies the combined effect of prolonged nightly fasting and metformin hydrochloride extended release in decreasing breast tumor cell proliferation and other biomarkers of breast cancer. Preventing invasive breast cancer or DCIS. Metformin is widely used to treat type II diabetes and is associated with a decreased risk of cancer and death in diabetic individuals. Intermittent fasting may protect cancer patients from the toxic effects of chemotherapy agents without causing ch... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma
Register for Updates
Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
NCT06095583
Recruiting
The Study is a Phase 3, randomized, three-arm, double-blind, placebo-controlled, multi-regional clinical research study to evaluate the safety and efficacy use of toripalimab alone or in combination with tifcemalimab as consolidation therapy in patients with limited-stage small cell lung cancer without disease progression following chemoradiotherapy. Tifcemalimab is a monoclonal antibody against B and T lymphocyte attenuator (BTLA). Toripalimab is a monoclonal antibody against programmed death... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: Millennium Physicians - Oncology, Houston, Texas
Conditions: Limited-stage Small Cell Lung Cancer (LS-SCLC)
Register for Updates